Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A Virus
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Influenza Infection
Conditions
Influenza Infection
Trial Timeline
Aug 21, 2023 → Jun 28, 2024
NCT ID
NCT05818124About Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A Virus
Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A Virus is a phase 1 stage product being developed by Merck for Influenza Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05818124. Target conditions include Influenza Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05818124 | Phase 1 | Completed |
Competing Products
20 competing products in Influenza Infection